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The dynamics of CD4+ effector T cells (Teff cells) and
CD4+Foxp3+ regulatory T cells (Treg cells) during
diabetes progression in nonobese diabetic mice
was investigated to determine whether an imbalance
of Treg cells and Teff cells contributes to the devel-
opment of type 1 diabetes. Our results demonstrated
a progressive decrease in the Treg cell:Teff cell ratio
in inflamed islets but not in pancreatic lymph nodes.
Intra-islet Treg cells expressed reduced amounts of
CD25 and Bcl-2, suggesting that their decline was
due to increased apoptosis. Additionally, administra-
tion of low-dose interleukin-2 (IL-2) promoted Treg
cell survival and protected mice from developing
diabetes. Together, these results suggest intra-islet
Treg cell dysfunction secondary to defective IL-2
production is a root cause of the progressive break-
down of self-tolerance and the development of
diabetes in nonobese diabetic mice.
INTRODUCTION
Type 1 diabetes (T1D), also known as autoimmune diabetes, re-
sults from autoimmune destruction of insulin-producing b cells in
the pancreatic islets of Langerhans. The disease is characterized
by a loss of blood-glucose homeostasis accompanied by inflam-
matory infiltrates in the islets. Both genetic and environmental
factors contribute to the development of the disease. Hallmarks
of human T1D are observed in the nonobese diabetic (NOD)
mouse, a strain identified 27 years ago in an inbred colony in
Japan (Makino et al., 1980). NOD mice provide a valuable tool
for dissection of the pathogenesis of T1D. Over 20 genetic loci,
termed insulin-dependent diabetes (Idd) loci, have been linked
to disease susceptibility in both human patients and NOD mice
(Todd and Wicker, 2001). Among these genes, those that encode
MHC class II, insulin, CTLA-4, and IL-2 have been identified as
contributors to the breakdown of central and/or peripheral toler-
ance, although the precise mechanisms associated with patho-genesis remain to be defined (Chentoufi and Polychronakos,
2002; Nakayama et al., 2005; Prochazka et al., 1987; Todd
et al., 1987; Ueda et al., 2003; Yamanouchi et al., 2007).
Circumstantial evidence suggests that regulatory T cells (Treg
cells) control the progression of diabetes. Disruption of Treg cell
development and homeostasis by blocking of the CD28-B7
pathway or IL-2 activity in NOD mice leads to acceleration of
diabetes (Salomon et al., 2000; Setoguchi et al., 2005). In addition,
Tcra/-deficient, Rag1/-deficient, or Foxp3-deficient scurfy
BDC2.5 T cell receptor (TCR)-transgenic mice, which are com-
pletely devoid of Treg cells, display no delay between the onset
of insulitis and the development of overt diabetes (Chen et al.,
2005). These findings suggest that diabetes onset might be as-
sociated with a reduction in Treg cell numbers and/or functions.
An alternative, but not mutually exclusive, explanation is that the
onset of diabetes is a result of the emergence of regulation-resis-
tant effector T cells (Teff cells). Studies of Treg cell dynamics in
human T1D patients have produced disparate results, ranging
from reduced Treg cell frequency (Kukreja et al., 2002) or func-
tion (Brusko et al., 2005; Lindley et al., 2005) to no changes
when comparing diabetic subjects to healthy control subjects
(Putnam et al., 2005). Three independent investigations of NOD
mice uniformly found an age-dependent decline in Treg cell
function (Gregori et al., 2003; Pop et al., 2005; You et al.,
2005). Two of these reports also demonstrated a reciprocal
age-dependent increase in Teff cell resistance to regulation.
However, data on the frequency of Treg cells in NOD mice are
inconclusive at present. One study reported an age-dependent
decline in the frequency of Foxp3-mRNA-expressing CD4+ cells
in the pancreatic lymph nodes (PLNs) and islets (Pop et al.,
2005), whereas another found an increase in Foxp3 mRNA at
the time of diabetes onset compared to 6-week-old prediabetic
control subjects (You et al., 2005).
Here, we report our study examining the population dynamics
of CD4+ Teff cells and Treg cells during the progression of T1D in
NOD mice. Our investigation revealed a paradoxical increase of
Treg cells in the PLN at the time of diabetes onset and demon-
strated that disease progression was associated with a loss of
Treg cell:Teff cell balance in the inflamed islets and concomitant
reduction of CD25 and Bcl-2 expression in intra-islet Treg cells.
Additionally, administration of IL-2 promoted Treg cell survivalImmunity 28, 687–697, May 2008 ª2008 Elsevier Inc. 687
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strates that cellular dynamics in local tissues play the key role
in determination of the balance of immune homeostasis and
disease progression. Our finding that IL-2 deficiency contributes
to intra-islet Treg cell dysfunction and progressive breakdown of
peripheral self-tolerance in the NOD mouse could have impor-
tant implications for the use of IL-2-modulating therapies for
the treatment of diabetes and other autoimmune diseases.
RESULTS
Preservation of Treg Cell:Teff Cell Balance
in the PLN at Diabetes Onset
To determine whether the onset of diabetes in NOD mice reflects
a general decline in Treg cells and an excess of autoreactive Teff
cells, we examined the Treg cell:Teff cell balance in the PLN of
the NOD mouse at different stages of disease progression in vivo.
Unexpectedly, the Treg cell fraction of the total CD4+ T cell pop-
ulation in the PLN did not decrease, but rather increased by
50%–70% at the time of diabetes onset (Figure 1A and Table
S1, available online). No significant change in the percentage
of Treg cells was found in distal inguinal LN (ILN) (Table S1).
The absolute number of total Treg cells in PLN at the time of
disease onset varied from mouse to mouse, mostly due to the
variation in the cellularity of the PLN. However, the increase in
the percentage of Treg cells at the time of disease onset was
consistently reproduced in a large number of mice followed dur-
ing a three-year study period, with the use of in situ detections
via immunohistochemistry (Figure 1B) and immunofluorescence
(see below) or more quantitative analyses via flow cytometry with
the use of two different clones of anti-Foxp3 mAb conjugated
with various fluorochromes.
Sustained Activation of PLN Treg Cells
To determine whether Treg cells present in the PLN at the time of
diabetes onset were functionally suppressive, we examined the
activation status of Treg cells. A higher fraction of PLN Treg cells
Figure 1. Preserved Treg Cell:Teff Cell Balance in PLN during
T1D Progression
(A) Flow-cytometric analysis of the percentage of Foxp3+ cells in the total
CD4+ T cell population of the PLNs of NOD mice. Representative histo-
grams from an 8-week-old prediabetic NOD mouse and a new-onset-
diabetic NOD mouse are shown.
(B) Immunohistochemistry of Foxp3 (brown) and B200 (pink) expression in
the PLNs of 6-week-old prediabetic NOD mice and new-onset-diabetic
NOD mice. Data represent five independent experiments with a total of
10–12 mice from each disease group.
showed reduced CD62L expression in newly diabetic mice
when compared to Treg cells in 6-week-old prediabetic
animals (Figure 2A), suggesting that Treg cells were more ac-
tivated in the PLN at the time of disease onset (Huehn et al.,
2004; Tang et al., 2004). Our previous work showed that Treg
cells effectively prevent the interaction of Teff cells with den-
dritic cells (DCs) (Tang et al., 2006). Thus, we transferred
CD4+CD25-CD62Lhi naive T cells from BDC2.5 TCR-trans-
genic mice and examined their interaction with endogenous
DCs in newly diabetic and 6-week-old prediabetic mice by
two-photon microscopy. Clustering and swarming of the islet-re-
active BDC2.5 T cells, indicative of their interaction with endog-
enous DCs, was absent in newly diabetic mice, in sharp contrast
with that found in the PLNs of 6-week-old prediabetic mice
(Figure 2B, Movies S1 and S2). Consistently, proliferation of
the adoptively transferred BDC2.5 T cells was markedly reduced
at the time of diabetes onset (Figure 2C). Sections of the PLN
were stained with mitotic marker Ki67, in addition to CD4 and
Foxp3, to compare levels of the priming of endogenous Teff cells
in the PLNs of young prediabetic and newly diabetic NOD mice.
A marked reduction in the number of proliferating endogenous
Teff cells (CD4+Foxp3) in the PLN at the time of disease onset
was evident, correlating with a concomitant increased number
of CD4+Foxp3+ Treg cells (Figure 2D). These results suggest
that the imbalance of Treg cells in the PLNs of newly diabetic
NOD mice prevented naive effector cells from becoming acti-
vated when recruited to the PLN at this late time point in disease
progression, although the reduced proliferation of Teff cells
could also be contributed to reduced availability of islet antigens
due to the reduction in b cell mass in overtly diabetic mice. It is
important to point out that the increase in Treg cells was specific
to the PLNs of the newly diabetic NOD mice (Table S1) and was
not observed in chronically diabetic animals (data not shown),
suggesting that the increase in Treg cells was dependent on
the presence of residual islet autoantigens. Taken together, our
results demonstrated an increased number and function of
Treg cells in the PLN as a result of sustained Treg cell activation,
leading to reduced Teff cell priming over the course of disease
progression.
Loss of Treg Cell:Teff Cell Balance in the Islets
Expansion of Treg cells during chronic inflammation has been re-
ported to be associated with disease resolution (Knoechel et al.,
2005; Korn et al., 2007). However, our results showed a relative
increase of Treg cells in the PLN with disease progression. This
paradoxical observation prompted us to analyze Treg cell dy-
namics in the islets of NOD mice. Because leukocyte infiltration688 Immunity 28, 687–697, May 2008 ª2008 Elsevier Inc.
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islets (Anderson and Bluestone, 2005), confocal microscopic
analyses of immunofluorescent antibody-stained pancreatic
sections were performed to characterize the Foxp3+CD4+ Treg
cell population within individual islets (Figure S1). Such analyses
revealed marked heterogeneity in the percentage of Treg cells,
from 5% to 30%, in individual islets. Although the total numbers
of Treg cells in each islet increased as the number of intra-islet
Teff CD4+ cells expanded (Figure S2), the percentage of Treg
cells dropped precipitously, revealing a striking inverse relation-
ship between the magnitude of infiltration and the percentage of
Treg cells in the individual islets (Figure 3A). The reduction in Treg
cell percentages was most pronounced in islets from prediabetic
mice that exhibited mild (grade 1) or moderate (grade 2) insulitis
(less than 500 CD4+ cells per islet section), suggesting that the
relative loss of Treg cells in the islets preceded the escalation
Figure 2. Preservation of Treg Cell Functions and Reduced
Teff Cell Priming in the PLN at the Time of Disease Onset
(A) Flow-cytometric analysis of CD62L expression in CD4+ Foxp3+ cells in
the PLNs of 6-week-old prediabetic NOD mice and new-onset-diabetic
NOD mice. The graph on the right is a summary of four independent exper-
iments comparing CD62L expression in CD4+CD25+ cells in the pancre-
atic LNs of young prediabetic (n = 9) and newly diabetic (n = 11) female
NOD mice.
(B) CD4+CD62L+CD25 cells from BDC2.5 T cell receptor transgenic mice
were purified by FACS, labeled with CFSE, and transferred to 6-week-old
prediabetic NOD mice and to mice that were within three days of diabetes
onset. The movement dynamics of transferred Treg cells in explanted
PLNs were monitored with two-photon laser-scanning microscopy. The
normalized average CFSE fluorescence intensity over a 30 min imaging
period is illustrated in the ‘‘heat maps’’ shown. The large aggregates of
strong fluorescence intensity represented by the yellow, red, and white
colors indicates restricted movement of cell clusters due to antigen recog-
nition, and the lower intensity represented by the blue, purple, and black
colors indicates random movement in the absence of antigen recognition.
(C) In vivo proliferation of transferred CD4+CD62L+CD25 cells from
BDC2.5 T cell receptor transgenic mice in PLNs of 6-week-old prediabetic
mice or new-onset-diabetic mice were determined by CFSE dilution
assay. Two representative histograms are shown.
(D) Proliferation of endogenous T cells in the PLNs of 6-week-old predia-
betic NOD mice and new-onset-diabetic NOD mice was determined by
costaining of PLN sections for the mitotic marker Ki67 (green), anti-CD4
(blue), and anti-Foxp3 (red). Representative micrographs are shown
(left), and the average numbers of Foxp3Ki67+ cells and Foxp3+ cells in
three randomly selected objective fields in the T cell zones of the PLNs
are summarized (right; mean ± standard deviation [SD]; n = 3 mice).
Results in each panel represent two to four independent experiments.
of inflammation and islet destruction. These results demon-
strated an uncoupling of the PLN and the pancreas in terms
of Treg cell:Teff cell balance over the course of the disease
and suggested that the progressive dysregulation of immune
homeostasis in islets led to b cell destruction and develop-
ment of diabetes.
Differential proliferation, trafficking, and/or survival of Teff
cells and Treg cells could explain the loss of Treg cell:Teff
cell balance in the islets. To compare the proliferation rate
of intra-islet Teff cells and Treg cells, we stained pancreatic
sections for Ki67 and determined the percentages of
proliferating Teff cells (CD4+Foxp3Ki67+) and Treg cells
(CD4+Foxp3+Ki67+) in individual islets. The total numbers of pro-
liferating Teff cells and Treg cells increased as the intra-islet
infiltrate expanded (Figures S3 and S4). A direct comparison of
Foxp3+ and Foxp3 cell proliferation rate in the same islets dem-
onstrated that higher percentages of Treg cells entered mitosis
in most of the islets examined independent of the age of the
mice (Figure 3B). Flow-cytometry analysis of Ki67 expression
by intra-islet Treg cells and Teff cells also demonstrated that
a higher fraction of Treg cells were in cycle as compared to
Teff cells (data not shown). Thus, the relative decline of Treg cells
seen in islets with increased infiltration was not due to a reduction
in Treg cell proliferation compared to that of Teff cells.
Defective Survival of Intra-Islet Treg Cells
We tested whether a defect in intra-islet Treg cell survival could
explain the relative loss of Treg cells. Because CD25 expressionImmunity 28, 687–697, May 2008 ª2008 Elsevier Inc. 689
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Regulatory T Cells in Type 1 DiabetesFigure 3. Dynamics of Teff Cells and Treg
Cells in the Islets of NOD Mice during
Diabetes Progression
(A) Numbers of CD4+ and Foxp3+ cells in individual
islets were quantified by manual counting of frozen
pancreatic sections strained with immunofluores-
cence-labeled antibodies. The percentages of
Foxp3+ Treg cells among CD4+ T cells in individual
islet sections are plotted against the total numbers
of CD4+ cells in the corresponding islet sections.
Correlation analysis revealed a significant inverse
correlation (Spearman r = 0.707) between the
numbers of total CD4+ T cells per islet section
and the percentage of Treg cells in the corre-
sponding islet (p < 0.0001).
(B) Numbers of Ki67+CD4+Foxp3,
Ki67CD4+Foxp3, Ki67+CD4+Foxp3+, and
Ki67CD4+Foxp3+ cells in individual islets were quantified as described in panel (A) legend. Percentages of proliferating (Ki67+) Treg cells versus proliferating
Teff cells in islets were calculated and plotted. For both panels, blue symbols represent islets from 6- to 8-week-old NOD mice, green symbols represent those
from 10- to 12-week-old mice, and red symbols represent those from mice with recent diabetes onset.is essential for Treg cell survival in response to IL-2 in the periph-
ery (D’Cruz and Klein, 2005; Fontenot et al., 2005a; Tang et al.,
2003), we measured CD25 expression in Foxp3+ cells in ILNs,
PLNs, and islets. Greater than 85% of Treg cells in the ILNs of
prediabetic and newly diabetic NOD mice expressed CD25, sim-
ilar to that reported for C57BL/6 mice (Fontenot et al., 2005b).
Treg cells in the PLN exhibited a moderate reduction of CD25
expression as compared to Treg cells in the ILN (Figure 4A). In
contrast, only 50% of intra-islet Treg cells expressed CD25
(Figure 4A). More strikingly, the mean fluorescent intensity of
CD25 staining in the intra-islet Foxp3+ cells was 20% of that of
their ILN counterparts (Figure 4B). The reduced CD25 expression
in intra-islet Treg cells was evident in young prediabetic mice,
coinciding with the shift in Treg cell:Teff cell balance in the islets
at the early phase of the pathogenic response (Figure 3A).
Foxp3+ cells from other inflammatory sites, such as lacrimal and
salivary glands, also exhibited lower CD25 expression (Fig-
ure S5), demonstrating that the loss of CD25 expression in Treg
cells at inflammatory sites was not an islet-specific phenome-
non, but rather a general deficiency in the NOD mice.
These data, combined with the increased proliferation of these
cells, are consistent with the notion that intra-islet Treg cells are
more prone to apoptosis. However, current methods for the
measuring of T cell apoptosis, including TUNEL, annexin V, or
caspase 3 staining, were not sensitive enough for in vivo analysis
because of the efficient removal of apoptotic cells by the scav-
enging system (Krysko et al., 2006). Therefore, we examined
the expression of an intracellular biochemical marker of IL-2-
driven cell survival, Bcl-2. Bcl-2 is an anti-apoptotic effector
molecule (Miyazaki et al., 1995), and its loss occurs at an early
stage of programmed cell death before the loss of cytoplasm-
membrane integrity and the subsequent sensing by the scaveng-
ing system. Bcl-2 was expressed at similar high amounts in both
Treg cells and Teff cells in inguinal and pancreatic LNs (Fig-
ure 4C). In contrast, Bcl-2 expression was significantly lower in
islet-infiltrating T cells, suggesting that levels of IL-2 were limiting
in the inflamed tissue. Most importantly, the reduction in Bcl-2
expression was more severe in intra-islet Treg cells (66% re-
duced as compared to LN-resident Treg cells) than in intra-islet
Teff cells (36% reduced as compared to LN-resident Teff cells)690 Immunity 28, 687–697, May 2008 ª2008 Elsevier Inc.(Figure 4D). We have examined Bcl-2 expression in mice of
a wide age range (from 8 to 25 weeks old), and we found that
the loss of Bcl-2 in intra-islet Treg cells was evident at the earliest
time examined and persisted through diabetes onset (data not
shown).
To directly determine if there is a local deficiency of IL-2 pro-
duction in the inflamed islets relative to LNs and spleens, we
purified CD4+ T cells and measured IL-2 mRNA expression by
real-time RT-PCR. Without in vitro stimulation, IL-2 mRNA was
present in all tissues at a low amount just above the detection
threshold (Figure 4E). IL-2 mRNA increased and become readily
detectable after three hours of stimulation with anti-CD3 and
anti-CD28. CD4+ cells from islets produced significantly lower
amounts of IL-2 mRNA as compared to CD4+ cells from spleen
or ILN (Figure 4E). Together, these findings suggest that a defect
in the survival of Treg cells, secondary to a deficiency in IL-2 pro-
duction, accounts for the selective loss of the Treg cell:Teff cell
balance in the islets.
Low-Dose IL-2 Promotes Treg Cell Survival
and Protects NOD Mice Against Diabetes
The hypothesis that the selective loss of the Treg cell:Teff cell
balance in the inflamed islets is due to enhanced apoptosis of in-
tra-islet Treg cells as a consequence of local IL-2 deficiency is
supported by previous studies demonstrating that the binding
of IL-2 to CD25 and the subsequent STAT5 signaling are essen-
tial for the survival of Foxp3+ Treg cells in the periphery (D’Cruz
and Klein, 2005; Fontenot et al., 2005a; Furtado et al., 2002). In
addition, IL-2 is one of the most potent inducers of CD25 and
Bcl-2 expression in T cells (Shi et al., 2001); thus, the loss of
CD25 and Bcl-2 strongly suggests an IL-2 deficiency. Further,
several publications have reported a relative IL-2 deficiency in
NOD mice, a defect mapped to the Idd3 locus on chromosome
3 (Denny et al., 1997; Yamanouchi et al., 2007). To test our hy-
pothesis that enhanced intra-islet Treg cell apoptosis secondary
to an IL-2 deficiency led to islet destruction, we initiated studies
to determine whether correction of the IL-2 deficiency would
improve Treg cell survival and confer disease protection. One-
week treatment of prediabetic NOD mice with a cocktail of 5 mg
recombinant IL-2 and 50 mg IL-2 mAbs, a regimen previously
Immunity
Regulatory T Cells in Type 1 DiabetesFigure 4. Loss of CD25 and Bcl-2 Expression in Intra-Islet Treg Cells
(A and B) Flow-cytometric analyses of CD25 expression in CD4+Foxp3+ cells. Representative CD25 versus Foxp3 dot plots of CD4+ cells in ILN, PLN, and islets
are shown in (A), along with a graph summarizing the mean fluorescence intensities of CD25 in CD4+Foxp3+ cells (B). The open symbols represent 8-week-old
mice, and filled symbols represent mice with recent diabetes onset. Results are representative of four independent experiments.
(C and D) Flow-cytometric analysis of Bcl-2 expression in CD4+Foxp3+ cells. Representative Bcl-2 (top) and isotype control staining (bottom) histograms of
CD4+Foxp3+ cells in ILN, PLN, and islets are shown in (C), along with a bar graph summarizing the mean fluorescence intensities of Bcl-2 expression in
CD4+Foxp3+ cells (D; mean ± SD, n = 4). Results are representative of five independent experiments.
(E) Real-time RT-PCR analysis of IL-2 mRNA in various lymphoid organs and islets. Tissue samples from prediabetic NOD female mice were assayed individually
(mean ± SD; n = 4). A student t test was performed to determine the statistical significance of the difference, and p values for the significantly different sample
pairs are shown on the graph.shown to selectively expand Treg cells without increasing CD8+
memory T cells in C57BL/6 mice (Boyman et al., 2006), led to
a marked increase in CD25 expression in Treg cells (Figure 5A)
and a systemic increase in the percentage of Treg cells (Fig-
ure 5B). At this dose, the treatment increased CD25 expression
on CD4+Foxp3 and CD8+ T cells of prediabetic NOD mice (Fig-
ures 5C and 5D). In addition, a substantial expansion of NK cells
were observed in LN and spleen and among islet infiltrates (Fig-
ure 5E). Notably, one week treatment at this dose in 10-week-old
female prediabetic mice rapidly precipitated diabetes and even
death in some animals (Figure 5F). Thus, high-dose IL-2 treat-ment enhanced functions of pathogenic Teff cells and the num-
ber of Treg cells, with a net result of accelerated autoimmune
tissue destruction.
Because Treg cells constitutively express CD25, a lower dose
of IL-2 treatment might selectively act on Treg cells with minimal
effect on CD4+ or CD8+ Teff cells. Using careful titration, we
found that one tenth of the dose used in the experiments shown
in Figure 5 led to a moderate increase in Treg cell percentages
(Figures 6A and 6D), correlating with an increase in their CD25
and Bcl-2 expression (Figures 6A–6C). At this dose, a mild in-
crease in CD4+ (Foxp3CD25hi) or CD8+ (CD25hi) Teff cellsImmunity 28, 687–697, May 2008 ª2008 Elsevier Inc. 691
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Regulatory T Cells in Type 1 DiabetesFigure 5. Effect of High-Dose IL-2 Treatment on Prediabetic NOD Mice
A cohort of 10-week-old female NOD mice were treated with daily intraperitoneal injections of 5 mg IL-2 and 50 mg of anti-IL-2 complex or irrelevant rat IgG as
control for five consecutive days (n = 3 per condition). One week after the initiation of the treatment, the composition of the spleen, PLN, and intra-islet infiltrates
were analyzed by flow cytometry.
(A) Dot plots displaying Foxp3 and CD25 expression in CD4+ cells in control- (top) and IL-2 complex-treated (bottom) mice.
(B–E). (B) Bar graphs summarizing the frequency of Treg cells and (C) CD25hiFoxp3 Teff cells among CD4+ cells, (D) the frequency of CD25hi cells among CD8+
cells, and (E) the percentage of NK cells among all CD45+ leukocytes are shown (mean ± SD; n = 3). The differences between control and IL-2-treated samples in
all organs analyzed were found to be significant (p < 0.05) by the student t test analysis. Results are representative of three independent experiments.
(F) A separate cohort of 10-week-old female NOD mice were treated with control rat IgG or IL-2 complex as in (A) (n = 10 per group). The percentage of mice who
died, became diabetic, or remained healthy one week after the treatment is summarized. Result is representative of three separate experiments.was observed (Figures 6E and 6F), and there was no marked ef-
fect on NK cells (Figure 6G). To determine the long-term effect of
the low-dose IL-2 therapy on diabetes development, a cohort of
female NOD mice was treated from 10 to 20 weeks of age. Con-
trol mice were treated with an anti-human HLA-Bw6 rat mAb or
saline for the same period. Low-dose IL-2 treatment prevented
diabetes development in the majority of the mice (Figure 7A).
Similar results were observed when mice were treated with re-
combinant human IL-2 from 5 to 20 weeks of age (Figure 7B).
These data were confirmed by histological examination of the
mice that remained free of diabetes at the end of the experiment.
There was a marked reduction in the severity of insulitis in the
mice that received IL-2 treatment (Figure 7C). Taken together,
our results suggest that the lower expression of CD25 in intra-is-
let Treg cells and their reduced survival were not due to defects
intrinsic to NOD Treg cells. Rather, the reduced availability of IL-
2 from the Teff cells is most likely the root cause of the progres-692 Immunity 28, 687–697, May 2008 ª2008 Elsevier Inc.sive loss of Treg cell:Teff cell balance in the islet leading to b cell
destruction.
DISCUSSION
In this study, we demonstrated that T1D progression in the NOD
mouse was associated with a progressive loss of Treg cell:Teff
cell balance in the inflamed islets but not in the PLN. Intra-islet
Treg cells expressed reduced amounts of CD25 and Bcl-2 rela-
tive to the Treg cells in the PLN, suggesting that the Treg cell:Teff
cell imbalance was due a defect in intra-islet Treg survival. We
further demonstrated that IL-2 treatment of NOD mice restored
CD25 expression in intra-islet Treg cells and led to diabetes
prevention.
It is well established that Treg cells control the progression of
T1D in the NOD-mouse model (Chen et al., 2005; Salomon et al.,
2000). However, the precise temporal and anatomical basis of
Immunity
Regulatory T Cells in Type 1 DiabetesFigure 6. Low-Dose IL-2 Therapy Restores Treg Cell:Teff Cell Balance
A cohort of 10-week-old female NOD mice were treated with daily injections of 0.5 mg IL-2 and 5 mg anti-IL-2 complex or irrelevant rat IgG as control for five
consecutive days. The expression of (A) CD25 and of (B and C) Bcl-2 in Treg cells in the PLN and the islets was determined by flow cytometry. Percentages
of (D) Treg cells, (E) Foxp-CD25hi CD4+ Teff cells, (F) CD25hi CD8+ Teff cells, and (G) NK cells are summarized (mean ± SD; n = 5 for [C], [D], and [G]; n = 3 for
[E] and [F]). p values for the samples that showed significant differences between control and IL-2-treated mice are indicated in the graphs, and those for all others
were not found to be significantly different by student t test (p > 0.05). Results are representative of at least three independent experiments.Treg cell control is not clear, especially in regards to the relevant
role of the PLN versus the inflamed islets as the major site of
immune regulation (Bour-Jordan et al., 2004; Chen et al., 2005;
Tang and Bluestone, 2006). In this study, we demonstrate that
NOD Treg cells mount an appropriate response to tissue de-
struction in the PLN by expanding, acquiring an activated pheno-
type, and infiltrating inflamed islets. This attempt to ‘‘control’’
disease was also manifested within the islets, given that a high
fraction of the Treg cells continue to divide within the pancreatic
islet tissue, suggesting that further activation occurred at the site
of inflammation. In fact, quantitative in vivo analysis of the Treg
cell:Teff cell balance in individual islets revealed a high frequency
of Treg cells in early islet infiltration in young prediabetic mice,
similar to what has been observed in other settings, including
models of tumor, infectious disease, and other autoimmune dis-
eases (Aluvihare and Betz, 2006; Belkaid et al., 2006; Munn and
Mellor, 2006; Rouse et al., 2006; Sakaguchi et al., 2006; Wald-
mann et al., 2006). However, in NOD mice, Treg cells failed to
survive in the tissue long term, which was probably due to the
limited availability of IL-2.
The importance of IL-2 in the maintenance of Treg cell homeo-
stasis and suppression of T1D has been suggested by IL-2-neu-tralization studies (Setoguchi et al., 2005). Genetic-mapping
studies have demonstrated that the NOD Idd3 allele contributes
to an IL-2 defect in the NOD mice (Denny et al., 1997). More re-
cently, an elegant study further demonstrated that the NOD idd3
allele led to systemic reduction in Treg cell frequency and higher
mortality due to diabetes in a CD8+ T cell-receptor-transgenic
NOD model (Yamanouchi et al., 2007). Our findings in this study
further illustrate that in untreated NOD mice, there is a selective
defect in Treg cell survival in inflamed tissues. The survival defect
was observed in mice as young as 6 weeks of age, supporting
the notion that this phenotype is most likely genetically encoded.
The reduced expression of IL-2 and IL-2-regulated genes such
as CD25 and Bcl-2 in Treg cells suggests that the Treg cell
survival defect was secondary to an IL-2 deficiency. The local
inflammatory milieu in the islets might exacerbate the IL-2 short-
age by further inhibiting IL-2 expression (Villarino et al., 2007),
competing for IL-2 by activated Teff cells, and inducing the
cleavage of CD25 via matrix metalloproteases induced by local
inflammation (Sheu et al., 2001). Thus, the genetically-encoded
inborn IL-2 deficiency in the NOD mice might be more pro-
nounced in inflamed tissues, thus compromising Treg cell sur-
vival locally. Common g-chain-binding cytokines such as IL-4,Immunity 28, 687–697, May 2008 ª2008 Elsevier Inc. 693
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Diabetes
(A and B) Diabetes progression in NOD mice
treated with (A) 0.5 mg IL-2 and 5 mg anti-IL-2 com-
plex or (B) recombinant human IL-2. Control mice
received saline. Shaded areas inside the graphs
indicate the duration of the treatments; between
10–20 weeks for mice indicated in (A) and between
5–20 weeks for mice indicated in (B). p values be-
tween the control and the IL-2-treated groups are
0.0002 for the experiment depicted in (A) and 0.11
for the experiment depicted in (B).
(C) Severity of intra-islet infiltration in mice that remain free of overt diabetes at the end of the experiment depicted in (B) was evaluated histologically, and the
percentage of islets with no infiltration (0), peri-insulitis (1), moderate insulitis with less than 50% islet area infiltrated (2), and severe insulitis with greater than 50%
islet area infiltrated (3) were determined and plotted. Data for the saline-treated control group represent 40 islets from four mice, and data from the IL-2-treated
group represent 341 islets from eight mice.IL-7, and IL-15 can help to sustain Treg cell survival in vitro
through the provision of anti-apoptosis signals (Pandiyan et al.,
2007). It is thus possible that deficiency in these cytokines could
also contribute to the demise of Treg cells in the inflamed islets.
Finally, it should be noted that the deficiency in Treg survival
might be compounded by an independent genetic defect in
Bcl-2 expression in NOD mice (Garchon et al., 1994). In fact,
overexpression of Bcl-2 in T cells and B cells alleviated insulitis
and conferred diabetes protection (Rietz et al., 2003).
Similar to intra-islet Treg cells, Treg cells isolated from in-
flamed lacrimal and salivary glands in the NOD mice also ex-
pressed markedly reduced CD25. Several published reports in
various disease models demonstrated that tissue-infiltrating
Treg cells could be readily identified by their surface expression
of CD25 and that the cells were functional in the control of local
inflammation (Belkaid et al., 2002; Yu et al., 2005). Thus, loss of
CD25 is not a general characteristic of Treg cells in inflamed
tissues. It remains to be determined whether the local IL-2
deficiency and Treg cell imbalance observed in this study were
restricted to sites of autoimmune inflammation or reflected
a more general defect of Treg cells in the NOD mouse. Examina-
tion of CD25 expression in Treg cells in other inflammatory
settings in the NOD mice, such as microbial infection, would
help to clarify this issue.
The polarized effect of high- and low-dose IL-2 therapy on
autoimmune response observed in this study is striking and high-
lights the pleiotropic effect of this cytokine. Although IL-2 has an
indispensable role in Treg cell homeostasis, it was originally dis-
covered as a T cell growth factor and activator of cytotoxic lym-
phocytes (Taniguchi et al., 1983). IL-2 has been used in the clinic
since the mid-1980s as an immune-boosting cancer therapy,
with limited success. Part of the limitations in IL-2 cancer therapy
might be due to the expansion of Treg cells (Wei et al., 2007). We
observed that a regimen of multiple, low-dose injections of IL-2
selectively supported the survival and growth of Treg cells over
that of Teff cells, whereas a high-dose regimen led to rapid
Teff cell expansion and disease onset. In light of this result, it is
interesting to point out that a high bolus dose of IL-2 was more
efficacious than a low dose in the treatment of renal cell carcino-
mas (Fisher et al., 2000; Yang et al., 2003). Together, the results
suggest that the in vivo effect of IL-2 can vary widely depending
on the dosing regimen, the amount of endogenous IL-2, and the
numbers of activated CD4 and CD8 Teff cells, NK cells, and Treg
cells in the host. Thus, an optimal IL-2 treatment regimen could694 Immunity 28, 687–697, May 2008 ª2008 Elsevier Inc.be difficult to predict for a heterogeneous patient population,
and adjunct therapy will be needed to ensure the desired out-
come. For example, the combination of IL-2 treatment with
Teff cell-depleting treatments such as anti-CD3 or Rapamycin
could prevent potential disease exacerbation and help to restore
long-term self tolerance in an autoimmune setting (Chatenoud,
2003; Rabinovitch et al., 2002). In contrast, in a cancer setting,
IL-2 treatment in conjunction with Treg cell depletion might be
more effective than IL-2 monotherapy for the induction of tumor
regression.
Three independent studies in the NOD mice demonstrated
that diabetes progression is associated with the acquisition of
regulation resistance by Teff cells over time (Gregori et al.,
2003; Pop et al., 2005; You et al., 2005). Our results extend these
findings, suggesting that the development of diabetes in the face
of increasing frequencies of Treg cells might reflect this in-
creased Teff cell resistance. The protracted disease course in
the NOD mice might reflect the time needed for regulation-resis-
tant Teff cells to emerge and accumulate to sufficient numbers
under the constant control of Treg cells. Furthermore, the regu-
lation-resistant phenotype could be linked to the reduced IL-2
production of these Teff cells. We previously demonstrated
that Treg cells expand in the presence of strong CD28 costimu-
lation, and large amounts of IL-2 can effectively prevent and even
reverse diabetes (Tang et al., 2004). These Treg cells survive
long-term (greater than 50 days) in recipient mice and are less
dependent on B7 costimulation and IL-2 from the hosts (Q.T.
and J.A.B., unpublished observations). Thus, the heightened
regulation resistance and unfavorable survival environment for
Treg cells found in the NOD mice can be overcome by Treg
cell therapies if appropriate Treg cell-preparative regimens are
used.
Immune deficiency is often associated with autoimmunity in
mice and man (Arkwright et al., 2002; Dupuis-Girod et al., 2003;
Horak et al., 1995; Mombaerts et al., 1993), and in the NOD
mouse, immune stimulation can protect mice against diabetes
(Qin and Singh, 1997; Sharif et al., 2001). Our findings provide
one possible explanation for these paradoxical observations,
suggesting that normal Treg cell homeostasis and a healthy bal-
anced immune system depend ultimately on a robust Teff cell re-
sponse. IL-2 production by activated Teff cells expands and sus-
tains Treg cells, which in turn feed back to suppress the Teff cell
response and maintain normal immune homeostasis. Disruption
of this crosstalk can lead to the dysregulation of the Treg cell:Teff
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Regulatory T Cells in Type 1 Diabetescell balance and contribute to the development of autoimmune
diseases in the NOD mice. The effective control of diabetes
with low-dose IL-2 treatment leads to an intriguing suggestion
that, in some instances, immune stimulation rather than immuno-
suppression could be an effective approach for the treatment of
autoimmune diseases.
EXPERIMENTAL PROCEDURES
Mice
Female NOD (Taconic, Germantown, NY) and NOD.BDC2.5 TCR-transgenic
mice were housed and bred under specific pathogen-free conditions at the
UCSF Animal Barrier Facility.
Treatment with IL-2
Eight- to ten-week-old female NOD mice were treated with an IL-2 and an anti-
IL-2 complex. A 100 ml PBS solution containing 0.5 to 5 mg recombinant mouse
IL-2 (eBioscience, San Diego, CA, USA) and 5 to 50 mg rat anti-mouse IL-2
(clone JES6-12A1, R & D Systems, Minneapolis, MN) was injected into the
peritoneal cavity of each mouse every day for five days. Control mice were
injected with either saline or 50 mg irrelevant mAb (rat anti-human HLA-Bw6).
For diabetes-prevention studies, female NOD mice were treated for five con-
secutive days followed by twice-per-week maintenance treatments for a total
duration of 10 weeks. Dosings for each specific experiment are indicated in the
Results section. In separate experiments, human recombinant IL-2 was used
at a dose of 25,000 international units three times per week for the duration as
indicated in the results section.
Flow Cytometry
Islets were purified, with standard collagenase protocols followed as de-
scribed (Tang et al., 2004), and dissociated by incubation with a nonenzymatic
solution (Sigma, St, Lois, MO, USA) followed by trituration per the manufac-
turer’s instructions. LN cells were made into a single cell suspension by
mechanic disruption or as described for islet cells. The following antibodies
were used to stain the cells: FITC- or PerCP-labeled anti-CD45 (LCA; BD Phar-
Mingen, San Diego, CA), Phycoerythrin (PE)- or FITC-labeled anti-CD25 (clone
PC61; eBioscience), PerCP- or Alexa 700-labeled anti-CD4 (BD PharMingen,
San Diego, CA, USA), FITC- or Alexa 700-conjugated anti-CD8 (Invitrogen,
Carlsbad, CA, USA), and biotinylated anti-NKG2D, followed by Quantumdot
605-labeled streptavidin (Invitrogen). The cells were then fixed, permeabilized,
and stained with APC-labeled Foxp3 antibody with the use of a Foxp3 labeling
kit per manufacturer’s instructions (eBioscience). Cell-surface staining with
anti-CD25 was omitted in some experiments in favor of intracellular staining
with PE anti-Bcl-2 (BD) and/or FITC anti-Ki67 (BD). Flow-cytometric analyses
were performed on an LSRII flow cytometer with FACS Diva software (Becton
Dickenson, San Jose, CA, USA).
Multicolor Immunofluorescent Labeling and Confocal Microscopy
The PLN and pancreata were harvested and frozen in OCT. Six micron cryosec-
tions were fixed in ethanol and incubated with rabbit anti-mouse Foxp3 (pro-
vided by R. Khattri) and biotinylated mouse monoclonal anti-Ki67, followed
by goat anti-rabbit Alexa 555 (Invitrogen), streptavidin FITC, and anti-CD4
Alexa 647 (eBioscience). The resulting fluorescent-staining pattern was de-
tected and acquired with an SP2 laser-scanning confocal microscope (Leica,
Wetzlar, Germany), and postacquisition analyses were performed with the
aid of the Metamorph software (Universal Imaging, Downingtown, PA, USA).
To quantify the numbers of CD4+Foxp3+, CD4+Foxp3, and Ki67+ cells within
each of the individual islets, a manual counting method was used with the aid of
the Metamorph software. High-resolution digitally zoomed images were used
to ensure accuracy in counting. Numbers obtained from contiguous nonover-
lapping regions of a single islet were added to derive a total number of Teff cells
and Treg cells in each islet. To compare the number of Treg cells and prolifer-
ating Teff cells in the PLNs of 6-week-old prediabetic NOD mice and recently
diabetic NOD mice, the numbers of CD4+Foxp3+ cells and CD4+Foxp3Ki67+
cells in nonoverlapping 105 pixel (one objective field) areas in the T cell zones
(indicated by continuous CD4 staining) were determined by manual counting
with the aid of the Metamorph software.Two-Photon Laser Scanning Microscopy Analysis
FACS-purified CD4+CD62LhiCD25 cells from NOD.BDC2.5 TCR-transgenic
mice were labeled with 5 mM carboxyfluorescein diacetate succinimidyl ester
(CFSE; Invitrogen) before retro-orbital injection into 6-week-old prediabetic or
recently diabetic NOD mice (3.5–53 106 per mouse). Two-photon microscopy
was performed with a custom resonant-scanning instrument as described
(Tang et al., 2006). In brief, PLN were excised, immobilized to coverslips
with the hilum of the LN facing away from the objective. During imaging, the
LNs were maintained in 36C RPMI medium bubbled with 95% O2/5% CO2,
and they were imaged through the capsule in a region distal to the hilum.
For time-lapse image acquisition, images of up to 50 xy planes with 2–5 mm
z spacing were acquired every 30 s for 30 to 60 min. Postacquisition data
analyses were performed with the aid of the Metamorph software (Universal
Imaging).
Quantification of IL-2 mRNA by Real-Time RT-PCR
Islet single-cell suspension was made as described in the section regarding
flow cytometry. CD4+ T cells from islets, ILN, PLN, and spleen were purified
by positive selection with autoMACS. Samples were kept separate per individ-
ual mice, and two thirds of the purified CD4+ cells from each sample were lysed
immediately after purification in Trizol (Invitrogen) for RNA isolation. The
remaining one third were stimulated in vitro with plate-bound anti-CD3 and
anti-CD28 (1 mg per ml each) for 16 hr before RNA isolation by Trizol. The
same amount of RNA was used to make cDNA with the use of oligo dT primers
and a reverse transcription kit per manufacturer’s instructions (SuperScript III
Reverse Transcription kit, Invitrogen). Then, 10% of each of the cDNA reac-
tions was used as a template for real-time PCR. The sequences for PCR
primers are: IL-2 forward, 50–AAAAGCTTTCAATTGGAAGATGCTG–30; IL-2 re-
verse, 50–TTGAGGGCTTGTTGAGATGA–30; b-actin forward, 50–AAGTGTGAC
GTTGACATCCGTAA–30; and b-actin reverse, 50–TGCCTGGGTACATGGTG
GTA–30. PCR was carried out with a Bio-Rad iQ5 Real-Time PCR Detection
System (Hercules, CA), and Cyber Green (Invitrogen) was used for the quanti-
tative detection of amplified DNA. Signals from the b-actin reactions were used
to normalize the signals in the IL-2 PCR reactions of the same cDNA sample to
derive the relative IL-2 mRNA level for each sample.
Statistical Analysis
To determine the relationship between the size of intra-islet infiltrates and the
percentage of Treg cells in individual islets, correlation analysis was performed
with the aid of GraphPad Prism software (San Diego, CA, USA). The Spearman
r value was calculated to determine the types of correlation (0 = no correlation,
0 to 1 = positive correlation, and1 to 0 = inverse correlation), and a two-tailed
p value was used to determine the significance of the correlation. To determine
the effect of IL-2 treatment on diabetes progression, diabetes-free fractions in
control groups and in those treated with IL-2 over time were calculated with the
Kaplan-Meier method, and the Log-rank test was used to compare the differ-
ences between the treatment groups. A two-tailed student t test was used to
determine the significance of the two different treatment groups as specified in
the Results section.
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